Yeah, we were quite surprised when I spoke to them and discovered this. In the future we might ask them to use all and increase the cycles to 14 or 15. That would explain A LOT of reasons why we are struggling with our samples (RNA, not so much for DNA).
-
-
Hi jteeee2,
I just wanted to check back in with you and say thank you. We did some testing in the lab and both the primers / Taq you recommended appeared to work well. We submitted that to our Sequencing CORE and we were able to save over 2/3's of those 68 samples. That a huge relief!!! So instead of all 4 out of 72, we now have material for 49. We have a plan to save those other 23 samples and we are asking them to increase the cycles from 12 for future RNA/FFPE runs.
Thank you so much.
SueComment
-
Glad to hear things are improving. Best of luck getting those last 23 samples made into libraries.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...Yesterday, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment